Could a new drug save pregnancies in women with a rare blood disorder?
NCT ID NCT03152058
First seen Apr 07, 2026 · Last updated Jun 20, 2026 · Updated 13 times
Summary
This study tests whether adding certolizumab (Cimzia) to standard care (heparin and aspirin) can prevent fetal death or early delivery in pregnant women with antiphospholipid syndrome (APS) and lupus anticoagulant. About 55 women will receive the drug early in pregnancy and be compared to a previous group. The goal is to see if this combination improves pregnancy outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital for Special Surgery
RECRUITINGNew York, New York, 10021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
TRIO Advancing Reproductive Care
RECRUITINGToronto, Ontario, M5G 2K4, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84132, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Certolizumab pegol (Cimzia)
What this could lead to
If it works, this could reduce the risk of fetal death or early delivery in pregnant women with antiphospholipid syndrome.
What could go wrong
This is a small Phase 2 trial with no placebo group, so results may not be definitive. The drug may not improve outcomes and could have unknown risks in pregnancy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.